DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Bafna Pharmaceuticals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·12 Oct 2026, 11:41 am

Bafna Pharmaceuticals

Bafna Pharmaceuticals Limited has submitted a compliance certificate to the stock exchanges. This document confirms that the company has fulfilled all its obligations under SEBI's Depositories and Participants Regulations for the quarter ending September 30, 2026.

This filing is a routine corporate disclosure required for listed companies. It serves as a confirmation of good governance and adherence to regulatory norms. For investors, this news is neutral and does not signal any operational changes or financial results.

Investors should treat this as a standard administrative update. The company is simply maintaining its compliance with market regulations. There are no immediate implications for the stock's price or the company's business operations.